|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000125744 |
Summary for RTN2 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000125744 | Gene symbol | RTN2 |
| Gene name | reticulon 2 | |
| HGNC | 10468 | |
| Entrez ID | 6253 | |
| Gene type | protein_coding | |
| Synonyms | RTN2|NSP2|NSPL1 | |
| UniProtAcc | O75298 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for RTN2 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| RTN2 | 7.35e+02 | -1.94e+00 | 1.97e-01 | -9.82e+00 | 9.07e-23 | 2.55e-21 | HNSC |
| RTN2 | 6.51e+02 | 1.02e+00 | 3.21e-01 | 3.17e+00 | 1.53e-03 | 8.75e-03 | ESCA |
| RTN2 | 4.36e+02 | 1.63e+00 | 4.09e-01 | 3.99e+00 | 6.50e-05 | 3.00e-04 | CHOL |
| Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Top |
Sex-biased somatic mutation for RTN2 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for RTN2 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg05534427 | chr19:45498292 | CGI:chr19:45498588-45499428 | promoter | 4.57e-01 | 3.54e-01 | 2.01e+00 | 4.46e-02 | 4.79e-02 | 1.03e-01 |
| STAD | cg03239386 | chr19:45496720 | CGI:chr19:45496503-45497240 | promoter,gene body | 1.75e-01 | 4.95e-01 | 9.24e+00 | 2.52e-20 | 2.95e-19 | -3.20e-01 |
| LIHC | cg03239386 | chr19:45496720 | CGI:chr19:45496503-45497240 | promoter,gene body | 2.22e-01 | 3.46e-01 | 5.04e+00 | 4.61e-07 | 6.68e-06 | -1.24e-01 |
| GBM | cg05534427 | chr19:45498292 | CGI:chr19:45498588-45499428 | promoter | 2.67e-01 | 3.87e-01 | -2.79e+00 | 5.24e-03 | 1.59e-02 | -1.20e-01 |
| DLBC | cg03239386 | chr19:45496720 | CGI:chr19:45496503-45497240 | promoter,gene body | 8.54e-01 | 2.00e-01 | 4.28e+00 | 1.84e-05 | 1.20e-04 | 6.54e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LIHC | cg06520812 | chr19:45497484 | CGI:chr19:45496503-45497240 | promoter | 5.29e-01 | 4.21e-01 | 3.65e+00 | 2.66e-04 | 4.90e-04 | 1.08e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg06520812 | chr19:45497484 | CGI:chr19:45496503-45497240 | promoter | 4.26e-01 | 2.59e-01 | 8.41e+00 | 4.04e-17 | 1.73e-16 | 1.68e-01 |
| BRCA | cg03213216 | chr19:45498477 | CGI:chr19:45498588-45499428 | promoter | 3.15e-01 | 1.98e-01 | 8.37e+00 | 5.66e-17 | 2.40e-16 | 1.17e-01 |
| BRCA | cg00116838 | chr19:45498488 | CGI:chr19:45498588-45499428 | promoter | 2.46e-01 | 1.09e-01 | 8.51e+00 | 1.73e-17 | 7.62e-17 | 1.37e-01 |
| HNSC | cg00116838 | chr19:45498488 | CGI:chr19:45498588-45499428 | promoter | 2.14e-01 | 9.40e-02 | 2.14e+00 | 3.25e-02 | 3.74e-02 | 1.20e-01 |
| COAD | cg03213216 | chr19:45498477 | CGI:chr19:45498588-45499428 | promoter | 2.43e-01 | 1.34e-01 | 3.18e+00 | 1.48e-03 | 3.94e-03 | 1.08e-01 |
| COAD | cg00116838 | chr19:45498488 | CGI:chr19:45498588-45499428 | promoter | 2.02e-01 | 7.65e-02 | 2.70e+00 | 6.91e-03 | 1.20e-02 | 1.25e-01 |
| BLCA | cg03213216 | chr19:45498477 | CGI:chr19:45498588-45499428 | promoter | 3.32e-01 | 1.99e-01 | 1.97e+00 | 4.94e-02 | 4.94e-02 | 1.33e-01 |
| BLCA | cg00116838 | chr19:45498488 | CGI:chr19:45498588-45499428 | promoter | 2.97e-01 | 1.10e-01 | 2.31e+00 | 2.08e-02 | 2.79e-02 | 1.86e-01 |
| LIHC | cg09444186 | chr19:45498347 | CGI:chr19:45498588-45499428 | promoter | 4.47e-01 | 3.44e-01 | 3.31e+00 | 9.25e-04 | 2.13e-03 | 1.03e-01 |
Top |
Exon skipping events with PSI in TCGA for RTN2 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for RTN2 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for RTN2 |
| TFs related to RTN2. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| RTN2 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for RTN2 |
| RBPs related to ES in RTN2. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| PAAD | RBM4 | exon_skip_319566 | 7.77e+00 | 3.67e-03 | 8.15e+00 | 9.88e-01 | Female-biased |
| PAAD | RBM8A | exon_skip_319566 | 1.02e+01 | 8.92e-03 | 1.05e+01 | 9.90e-01 | Female-biased |
| RTN2 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
| ENSG00000125744 | NNT-AS1,hsa-mir-431,RTN2 | Male-specific ceRNA | TCGA-HNSC |
| ENSG00000125744 | PRECSIT,hsa-mir-665,RTN2 | Male-specific ceRNA | TCGA-HNSC |
| ENSG00000125744 | AC093010.2,hsa-mir-93,RTN2 | Male-specific ceRNA | TCGA-HNSC |
| ENSG00000125744 | NAMA,hsa-mir-93,RTN2 | Male-specific ceRNA | TCGA-HNSC |
| ENSG00000125744 | AC104836.1,hsa-mir-93,RTN2 | Male-specific ceRNA | TCGA-HNSC |
| ENSG00000125744 | AC012085.2,hsa-mir-93,RTN2 | Male-specific ceRNA | TCGA-HNSC |
| ENSG00000125744 | NNT-AS1,hsa-mir-93,RTN2 | Male-specific ceRNA | TCGA-HNSC |
| ENSG00000125744 | LINC02202,hsa-mir-93,RTN2 | Male-specific ceRNA | TCGA-HNSC |
| ENSG00000125744 | AL137782.1,hsa-mir-93,RTN2 | Male-specific ceRNA | TCGA-HNSC |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs73053415 | chr19:51531085:G:A | - | 0.116361344267797 | 0.021795165425082 | STAD | Female-baised eQTL |
| rs78269716 | chr19:51531886:A:G | - | 0.116361344267797 | 0.021795165425082 | STAD | Female-baised eQTL |
| rs77020082 | chr19:51527894:T:G | - | 0.179551896022127 | 0.00092624816516599 | LGG | Female-baised eQTL |
| rs79864857 | chr19:51529085:C:T | - | 0.171731590795035 | 0.00360680436828256 | LGG | Female-baised eQTL |
| rs74352887 | chr19:51529854:G:A | - | 0.159119423169333 | 0.0189990536005502 | LGG | Female-baised eQTL |
| rs57056811 | chr19:53697668:T:C | - | 0.0606597085650775 | 0.0343438679384927 | LUAD | Female-baised eQTL |
| rs10402234 | chr19:53696545:C:G | - | 0.060281246890178 | 0.0372929928543957 | LUAD | Female-baised eQTL |
| rs11882412 | chr19:44134783:G:A | - | -0.10739296451753 | 0.0188057597216033 | COAD | Female-baised eQTL |
| rs57146784 | chr19:38380150:A:G | - | 0.146689891926321 | 0.0267665229042307 | COAD | Female-baised eQTL |
| rs1077994 | chr19:38374059:T:A | - | 0.159342680166324 | 0.0279681446906374 | COAD | Female-baised eQTL |
| rs12609258 | chr19:38358675:G:A | - | 0.143613005413503 | 0.0497656033466108 | COAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs35080293 | chr19:44993366:T:G | - | 0.0608429771988334 | 0.0285189608753388 | LIHC | Male-baised eQTL |
| rs60876330 | chr19:44984875:C:T | - | 0.0607960453716435 | 0.0287745935612709 | LIHC | Male-baised eQTL |
| rs56803710 | chr19:44978627:C:T | - | 0.0606254839219561 | 0.0295881521904226 | LIHC | Male-baised eQTL |
| rs7253458 | chr19:44979313:C:T | - | 0.0606254839219561 | 0.0295881521904226 | LIHC | Male-baised eQTL |
| rs55762617 | chr19:44982205:C:A | - | 0.0606254839219561 | 0.0295881521904226 | LIHC | Male-baised eQTL |
| rs55778858 | chr19:44982208:G:A | - | 0.0606254839219561 | 0.0295881521904226 | LIHC | Male-baised eQTL |
| rs11083755 | chr19:44986807:C:T | - | 0.0606254839219561 | 0.0295881521904226 | LIHC | Male-baised eQTL |
| rs2075618 | chr19:44992410:G:C | - | 0.0606254839219561 | 0.0295881521904226 | LIHC | Male-baised eQTL |
| rs892131 | chr19:44993738:C:T | - | 0.0606254839219561 | 0.0295881521904226 | LIHC | Male-baised eQTL |
| rs73047694 | chr19:44994594:G:A | - | 0.0606254839219561 | 0.0295881521904226 | LIHC | Male-baised eQTL |
| rs2075620 | chr19:44976780:A:G | - | 0.0605254225187104 | 0.0301074329513415 | LIHC | Male-baised eQTL |
| rs112704499 | chr19:44964441:G:A | - | 0.0603064485538576 | 0.0313182957576559 | LIHC | Male-baised eQTL |
| rs2142074 | chr19:44969840:A:G | - | 0.0603064485538576 | 0.0313182957576559 | LIHC | Male-baised eQTL |
| rs11668758 | chr19:44971423:C:T | - | 0.0603064485538576 | 0.0313182957576559 | LIHC | Male-baised eQTL |
| rs11665849 | chr19:44971580:T:G | - | 0.0603064485538576 | 0.0313182957576559 | LIHC | Male-baised eQTL |
| rs11669609 | chr19:44971619:C:T | - | 0.0603064485538576 | 0.0313182957576559 | LIHC | Male-baised eQTL |
| rs1882752 | chr19:44958085:G:C | - | 0.0603011076537619 | 0.0314493328089993 | LIHC | Male-baised eQTL |
| rs934427 | chr19:44975559:T:G | - | 0.0602603393568292 | 0.0316715173171353 | LIHC | Male-baised eQTL |
| rs2238682 | chr19:44955336:C:T | - | 0.059682494095067 | 0.0343241172620369 | LIHC | Male-baised eQTL |
| rs7252480 | chr19:44955668:C:T | - | 0.059682494095067 | 0.0343241172620369 | LIHC | Male-baised eQTL |
| rs12979040 | chr19:36190516:C:T | - | 0.0593741737395899 | 0.046175214986656 | LUSC | Male-baised eQTL |
| rs10415869 | chr19:49700328:G:A | - | 0.0568357230152713 | 0.0385092758692136 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000125744 |
| CpG Site: cg18226166 | |
| Position to Gene: gene | |
| Male Effect: 0.0839288977164748 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg18226166 | chr19:45493643 | gene | 0.0839288977164748 | 1.04709330129566e-06 | 0.38653451206667777 | 2.3214208500569823e-09 | LUAD |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of RTN2 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000125744 | RTN2 | C1858106 | SPASTIC PARAPLEGIA 12, AUTOSOMAL DOMINANT (disorder) | 1 | CTD_human |
